Category: DIAN Scientific Advancements

First Subject Enrolled in Phase II/III Study of Eisai’s Anti-MTBR Tau Antibody E2814 for Dominantly Inherited Alzheimer’s Disease (DIAD), conducted by DIAN-TU

Eisai Co., Ltd. - Jan 19 2022

In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned

Alzforum - Apr 10, 2020

Confused About the DIAN-TU Trial Data? Experts Discuss Nuances

Alzforum - Apr 10, 2020

Topline Result for First DIAN-TU Clinical Trial: Negative on Primary

Alzforum - Feb 10 2020

Bateman receives Potamkin Award for Alzheimer’s research

Washington University School of Medicine news release, March 20, 2019

Timeline of the the Dominantly Inherited Alzheimer Network

St. Louis Post-Dispatch, February 9, 2019

Stop Alzheimer’s before it starts